These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7409859)

  • 1. Immunosuppression in BALB/c mice bearing the plasmacytoma TEPC-183: massive increase in red pulp macrophages induced by the tumour.
    Joshua DE; Humphrey JH; Grennan D; Brown G
    Immunology; 1980 Jun; 40(2):223-8. PubMed ID: 7409859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression in plasmacytoma: induction of suppressor cells.
    Chen Y; Hwang LT; Heller P
    Clin Exp Immunol; 1982 Jan; 47(1):191-6. PubMed ID: 6212173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosupression of the primary and secondary immune response by an IgM plasmacytoma (TEPC-183).
    Havas HF; Schiffman GD; Fenton M; Goodis A; Braverman S
    Immunology; 1979 Feb; 36(2):191-7. PubMed ID: 35463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of splenectomy on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).
    Havas HF; Berney S; Goodis A; Schiffman G
    Cancer Res; 1979 Sep; 39(9):3783-7. PubMed ID: 476702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of T, B and adherent cells in the in vitro immune response of TEPC-183-bearing mice.
    Patel M; Havas HF
    Immunology; 1982 May; 46(1):97-105. PubMed ID: 6978846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.
    Shanahan TC; Ceglowski WS; Havas HF
    Cancer Res; 1985 Dec; 45(12 Pt 1):6463-70. PubMed ID: 2866030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice.
    Havas HF; Schiffman G
    Immunology; 1978 Jan; 34(1):1-8. PubMed ID: 23993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of the humoral immune response by plasmacytomas: mediation by adherent mononuclear cells.
    Kolb JP; Arrian S; Zolla-Pazner S
    J Immunol; 1977 Feb; 118(2):702-9. PubMed ID: 138708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mode of action of splenic suppressor cells in murine plasmacytoma.
    Chen Y; Heller P
    Clin Exp Immunol; 1981 Sep; 45(3):514-22. PubMed ID: 6461449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of lipocortin I in macrophage-mediated immunosuppression in tumor-bearing mice.
    Sakata T; Iwagami S; Tsuruta Y; Teraoka H; Hojo K; Suzuki S; Sato K; Suzuki R
    J Immunol; 1990 Jul; 145(1):387-96. PubMed ID: 2141618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of B-lymphocyte clonal proliferation by spleen cells from plasmacytoma-bearing mice.
    Hamburger AW
    J Natl Cancer Inst; 1980 Dec; 65(6):1337-43. PubMed ID: 6968847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune suppression in BALB/c mice bearing the plasmacytoma TEPC-183: evidence for normal lymphocyte but defective macrophage function.
    Joshua DE; Brown G; MacLennan IC
    Int J Cancer; 1979 May; 23(5):663-72. PubMed ID: 378867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of TEPC-183 plasmacytoma on resistance of passively or actively immunized BALB/c mice to infection with Streptococcus pneumoniae.
    Havas HF; Schiffman G; Schmitz J
    Cancer Res; 1984 Aug; 44(8):3299-302. PubMed ID: 6744264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Origin and function of suppressor macrophages in myeloma.
    Kennard J; Zolla-Pazner S
    J Immunol; 1980 Jan; 124(1):268-73. PubMed ID: 6965292
    [No Abstract]   [Full Text] [Related]  

  • 17. Diffusible suppressor factor from splenic macrophages in murine plasmacytoma.
    Chen YH; Heller P
    Clin Exp Immunol; 1984 Jul; 57(1):171-7. PubMed ID: 6378461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody against the antigen receptor of a plasmacytoma prolongs survival of mice bearing the tumor.
    Beatty PG; Kim BS; Rowley DA; Coppleson LW
    J Immunol; 1976 May; 116(5):1391-6. PubMed ID: 1270800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.
    Mokyr MB; Braun DP; Dray S
    Cancer Res; 1979 Mar; 39(3):785-92. PubMed ID: 427766
    [No Abstract]   [Full Text] [Related]  

  • 20. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.